Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 10/20 | 0.44 |
| ▸ | PPARA | Q07869 | 9/20 | 0.44 |
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2902922 | 0.94 | PPARD (0.47) | PPARDPPARAPPARGSTAT3HTR7 | |
| SCHEMBL4808451 | 0.88 | PPARA (0.59) | PPARDPPARAPPARG | |
| SCHEMBL4804485 | 0.87 | PPARA (0.48) | PPARDPPARAPPARGMAPT | |
| SCHEMBL5999249 | 0.87 | PPARD (0.42) | PPARDPPARAPPARGHTR7TP53 | |
| SCHEMBL14411904 | 0.86 | PPARD (0.44) | PPARDPPARAPPARGHTR7HTR1A | |
| SCHEMBL4808683 | 0.86 | PPARD (0.51) | PPARDPPARAPPARGHTR1A | |
| SCHEMBL4851159 | 0.85 | PPARD (0.51) | PPARDPPARAPPARGHTR7MCL1 | |
| SCHEMBL2065429 | 0.85 | PPARD (0.44) | PPARDPPARAPPARGMCL1TP53 | |
| SCHEMBL4806322 | 0.84 | PPARD (0.43) | PPARDPPARAPPARGHTR7HTR1A | |
| SCHEMBL4808137 | 0.84 | PPARA (0.57) | PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541456-B2 | Roflumilast for the treatment of diabetes mellitus type 2 | TAKEDA GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541456-B2 | Roflumilast for the treatment of diabetes mellitus type 2 | TAKEDA GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | PPARD, PPARA, PPARG | PPARD 1/4885PPARA 2/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.